Cargando…
Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells
The bisindole indirubin has been described, more than 30 years ago, as being clinically active in the treatment of human chronic myelocytic leukaemia. However, the underlying mechanism of action has remained unclear. We have reported previously that indirubin and its analogues are potent and selecti...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2001
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363695/ https://www.ncbi.nlm.nih.gov/pubmed/11161389 http://dx.doi.org/10.1054/bjoc.2000.1546 |